Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

Berenberg lowered the firm’s price target on Moderna (MRNA) to $28 from $30 and keeps a Hold rating on the shares. The firm thinks BioNTech’s ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...